S&P 500   3,383.92 (+1.51%)
DOW   27,962.16 (+0.99%)
QQQ   272.58 (+2.79%)
AAPL   449.76 (+2.80%)
MSFT   208.91 (+2.72%)
FB   260.71 (+1.79%)
GOOGL   1,505.20 (+1.67%)
AMZN   3,155.67 (+2.43%)
NVDA   454.73 (+4.78%)
CGC   17.40 (+2.65%)
BABA   255.74 (+2.95%)
TSLA   1,527.24 (+11.12%)
GE   6.63 (-1.49%)
MU   48.33 (+1.19%)
AMD   82.24 (+6.97%)
T   30.20 (-0.26%)
F   7.11 (-1.66%)
ACB   9.92 (-1.00%)
GILD   68.86 (+1.12%)
NFLX   479.79 (+2.75%)
DIS   131.35 (+0.66%)
BAC   26.56 (-1.34%)
BA   173.96 (-3.43%)
S&P 500   3,383.92 (+1.51%)
DOW   27,962.16 (+0.99%)
QQQ   272.58 (+2.79%)
AAPL   449.76 (+2.80%)
MSFT   208.91 (+2.72%)
FB   260.71 (+1.79%)
GOOGL   1,505.20 (+1.67%)
AMZN   3,155.67 (+2.43%)
NVDA   454.73 (+4.78%)
CGC   17.40 (+2.65%)
BABA   255.74 (+2.95%)
TSLA   1,527.24 (+11.12%)
GE   6.63 (-1.49%)
MU   48.33 (+1.19%)
AMD   82.24 (+6.97%)
T   30.20 (-0.26%)
F   7.11 (-1.66%)
ACB   9.92 (-1.00%)
GILD   68.86 (+1.12%)
NFLX   479.79 (+2.75%)
DIS   131.35 (+0.66%)
BAC   26.56 (-1.34%)
BA   173.96 (-3.43%)
S&P 500   3,383.92 (+1.51%)
DOW   27,962.16 (+0.99%)
QQQ   272.58 (+2.79%)
AAPL   449.76 (+2.80%)
MSFT   208.91 (+2.72%)
FB   260.71 (+1.79%)
GOOGL   1,505.20 (+1.67%)
AMZN   3,155.67 (+2.43%)
NVDA   454.73 (+4.78%)
CGC   17.40 (+2.65%)
BABA   255.74 (+2.95%)
TSLA   1,527.24 (+11.12%)
GE   6.63 (-1.49%)
MU   48.33 (+1.19%)
AMD   82.24 (+6.97%)
T   30.20 (-0.26%)
F   7.11 (-1.66%)
ACB   9.92 (-1.00%)
GILD   68.86 (+1.12%)
NFLX   479.79 (+2.75%)
DIS   131.35 (+0.66%)
BAC   26.56 (-1.34%)
BA   173.96 (-3.43%)
S&P 500   3,383.92 (+1.51%)
DOW   27,962.16 (+0.99%)
QQQ   272.58 (+2.79%)
AAPL   449.76 (+2.80%)
MSFT   208.91 (+2.72%)
FB   260.71 (+1.79%)
GOOGL   1,505.20 (+1.67%)
AMZN   3,155.67 (+2.43%)
NVDA   454.73 (+4.78%)
CGC   17.40 (+2.65%)
BABA   255.74 (+2.95%)
TSLA   1,527.24 (+11.12%)
GE   6.63 (-1.49%)
MU   48.33 (+1.19%)
AMD   82.24 (+6.97%)
T   30.20 (-0.26%)
F   7.11 (-1.66%)
ACB   9.92 (-1.00%)
GILD   68.86 (+1.12%)
NFLX   479.79 (+2.75%)
DIS   131.35 (+0.66%)
BAC   26.56 (-1.34%)
BA   173.96 (-3.43%)
Log in

NASDAQ:CDLXCardlytics Stock Price, Forecast & News

$75.26
+3.17 (+4.40 %)
(As of 08/12/2020 02:11 PM ET)
Add
Compare
Today's Range
$73.74
Now: $75.26
$78.59
50-Day Range
$65.82
MA: $71.34
$79.17
52-Week Range
$27.33
Now: $75.26
$107.50
Volume14,966 shs
Average Volume564,853 shs
Market Capitalization$2.05 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.38
Cardlytics, Inc. operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. It also provides solutions that enable marketers and marketing service providers to leverage the power of purchase intelligence outside the banking channel. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Read More
Cardlytics logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.1Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.58 out of 5 stars


Industry, Sector and Symbol

Industry Computer programming, data processing, & other computer related
Sub-IndustryN/A
Current SymbolNASDAQ:CDLX
CUSIPN/A
Phone888-798-5802

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$210.43 million
Book Value$4.78 per share

Profitability

Net Income$-17,140,000.00

Miscellaneous

EmployeesN/A
Market Cap$2.05 billion
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$75.26
+3.17 (+4.40 %)
(As of 08/12/2020 02:11 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CDLX News and Ratings via Email

Sign-up to receive the latest news and ratings for CDLX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cardlytics (NASDAQ:CDLX) Frequently Asked Questions

How has Cardlytics' stock been impacted by COVID-19 (Coronavirus)?

Cardlytics' stock was trading at $45.83 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CDLX shares have increased by 66.9% and is now trading at $76.47.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Cardlytics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardlytics in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Cardlytics
.

When is Cardlytics' next earnings date?

Cardlytics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Cardlytics
.

How were Cardlytics' earnings last quarter?

Cardlytics Inc (NASDAQ:CDLX) released its earnings results on Tuesday, August, 4th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.36. The business had revenue of $28.22 million for the quarter, compared to analyst estimates of $30.84 million. Cardlytics had a negative return on equity of 26.42% and a negative net margin of 18.86%. The firm's revenue was down 42.1% on a year-over-year basis. During the same period in the previous year, the company earned ($0.12) earnings per share.
View Cardlytics' earnings history
.

What price target have analysts set for CDLX?

6 equities research analysts have issued 12 month target prices for Cardlytics' stock. Their forecasts range from $26.00 to $75.00. On average, they anticipate Cardlytics' share price to reach $55.17 in the next year. This suggests that the stock has a possible downside of 27.9%.
View analysts' price targets for Cardlytics
.

Has Cardlytics been receiving favorable news coverage?

News stories about CDLX stock have been trending negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cardlytics earned a coverage optimism score of -2.2 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next several days.
View the latest news about Cardlytics
.

Are investors shorting Cardlytics?

Cardlytics saw a drop in short interest in the month of January. As of January 31st, there was short interest totaling 2,770,000 shares, a drop of 19.5% from the January 15th total of 3,440,000 shares. Based on an average daily trading volume, of 559,900 shares, the short-interest ratio is currently 4.9 days.
View Cardlytics' Short Interest
.

Who are some of Cardlytics' key competitors?

What other stocks do shareholders of Cardlytics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardlytics investors own include Alibaba Group (BABA), NVIDIA (NVDA), Trade Desk (TTD), Caterpillar (CAT), Walt Disney (DIS), Docusign (DOCU), Advanced Micro Devices (AMD), Roku (ROKU), Square (SQ) and Twilio (TWLO).

Who are Cardlytics' key executives?

Cardlytics' management team includes the following people:
  • Mr. Scott D. Grimes, Co-Founder, CEO & Director (Age 56)
  • Ms. Lynne Marie Laube, Co-Founder, COO & Director (Age 49)
  • Mr. David Evans, CFO & Head of Corp. Devel.
  • Mr. Sathish Gaddipati, Chief Technology Officer (Age 52)
  • Mr. Kirk L. Somers, Chief Legal & People Officer (Age 54)

When did Cardlytics IPO?

(CDLX) raised $76 million in an IPO on Friday, February 9th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. BofA Merrill Lynch and J.P. Morgan acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey, Raymond James and KeyBanc Capital Markets were co-managers.

What is Cardlytics' stock symbol?

Cardlytics trades on the NASDAQ under the ticker symbol "CDLX."

Who are Cardlytics' major shareholders?

Cardlytics' stock is owned by a number of retail and institutional investors. Top institutional investors include Frontier Capital Management Co. LLC (1.67%), Jennison Associates LLC (1.63%), Victory Capital Management Inc. (1.16%), Great Lakes Advisors LLC (0.72%), Rockefeller Capital Management L.P. (0.61%) and Ziegler Capital Management LLC (0.34%). Company insiders that own Cardlytics stock include Aimia Inc, Andrew Christiansen, Bryce Youngren, Clifford Sosin, David Leslie Adams, David Thomas Evans, John L Jr Klinck, John V Balen, Kirk Somers, Lynne Marie Laube, Mark A Johnson, Polaris Venture Management Co, Scott D Grimes and Tony Weisman.
View institutional ownership trends for Cardlytics
.

Which institutional investors are selling Cardlytics stock?

CDLX stock was sold by a variety of institutional investors in the last quarter, including RMB Capital Management LLC, Frontier Capital Management Co. LLC, Hancock Whitney Corp, Hussman Strategic Advisors Inc., Jennison Associates LLC, and Brave Asset Management Inc.. Company insiders that have sold Cardlytics company stock in the last year include Aimia Inc, Andrew Christiansen, Bryce Youngren, David Leslie Adams, David Thomas Evans, John L Jr Klinck, Kirk Somers, Lynne Marie Laube, Mark A Johnson, Scott D Grimes, and Tony Weisman.
View insider buying and selling activity for Cardlytics
.

Which institutional investors are buying Cardlytics stock?

CDLX stock was bought by a variety of institutional investors in the last quarter, including Great Lakes Advisors LLC, First Trust Advisors LP, Serengeti Asset Management LP, Tygh Capital Management Inc., California Public Employees Retirement System, Ziegler Capital Management LLC, Roubaix Capital LLC, and Victory Capital Management Inc.. Company insiders that have bought Cardlytics stock in the last two years include Clifford Sosin, and John V Balen.
View insider buying and selling activity for Cardlytics
.

How do I buy shares of Cardlytics?

Shares of CDLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cardlytics' stock price today?

One share of CDLX stock can currently be purchased for approximately $76.47.

How big of a company is Cardlytics?

Cardlytics has a market capitalization of $2.09 billion and generates $210.43 million in revenue each year. The company earns $-17,140,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis.

What is Cardlytics' official website?

The official website for Cardlytics is www.cardlytics.com.

How can I contact Cardlytics?

Cardlytics' mailing address is 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308. The company can be reached via phone at 888-798-5802 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.